NeuroBo Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
NeuroBo Pharmaceuticals has a total shareholder equity of $16.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $22.8M and $6.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$22.44m |
| Equity | US$16.69m |
| Total liabilities | US$6.10m |
| Total assets | US$22.78m |
Recent financial health updates
Recent updates
NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Sep 29Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely
Sep 14
NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split
Sep 12NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases
Nov 25NeuroBo on track to post a record gain after announcing a special meeting
Jun 14NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition
Jan 06Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like
Dec 21NeuroBo Pharmaceuticals EPS misses by $0.02
Nov 13Financial Position Analysis
Short Term Liabilities: NRBO's short term assets ($22.5M) exceed its short term liabilities ($6.0M).
Long Term Liabilities: NRBO's short term assets ($22.5M) exceed its long term liabilities ($136.0K).
Debt to Equity History and Analysis
Debt Level: NRBO is debt free.
Reducing Debt: NRBO has no debt compared to 5 years ago when its debt to equity ratio was 3.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NRBO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NRBO has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 5.9% each year.